kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human CTLA4 /CD152 Protein, With C-Fc Tag, 200µg  

Recombinant Human CTLA4 /CD152 Protein, With C-Fc Tag, 200µg

Recombinant Human CTLA4 /CD152 Protein, With C-Fc Tag (rh CTLA4 /CD152 Fc Chimera) Ala 37 - Ser 160 was produced in human HEK293 cells, Fc Tag (MALS verified)

recombinant human protein CTLA4, CD152

More details


Availability: within 7 days

234,00 €

CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) is also known as CD152 (Cluster of differentiation 152), is a protein receptor that downregulates the immune system. CTLA4 is a member of the immunoglobulin superfamily, which is expressed on the surface of Helper T cells and transmits an inhibitory signal to T cells. The protein contains an extracellular V domain, a transmembrane domain, and a cytoplasmic tail. Alternate splice variants, encoding different isoforms. CTLA4 is similar to the T-cell co-stimulatory protein, CD28, and both molecules bind to CD80 and CD86, also called B7-1 and B7-2 respectively, on antigen-presenting cells. CTLA4 transmits an inhibitory signal to T cells, whereas CD28 transmits a stimulatory signal. Intracellular CTLA4 is also found in regulatory T cells and may be important to their function. Fusion proteins of CTLA4 and antibodies (CTLA4-Ig) have been used in clinical trials for rheumatoid arthritis.

Recombinant Human CTLA4 /CD152 Protein, Fc Tag (CT4-H5255) is expressed from human 293 cells (HEK293). It contains AA Ala 37 - Ser 160 (Accession # P16410-1).
Predicted N-terminus: Ala 37

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 39.9 kDa. The protein migrates as 45-55 kDa under reducing (R) condition, and 90 kDa under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.

Less than 1.0 EU per μg by the LAL method.

>98% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

See Certificate of Analysis for reconstitution instructions and specific concentrations.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Please refer to product data sheet.

Clinical and Translational Updates

(1) "Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradation"
Xu, Xie, Zhou et al
Nat Commun (2024) 15 (1), 4237
(2) "Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma"
Leek, Notohardjo, de Joode et al
Sci Rep (2024) 14 (1), 11244
(3) Pituitary-related immune adverse events induced by programmed death Protein-1 inhibitors differ clinically from hypophysitis"
Yang, Zhang, Chen et al
Clin Endocrinol (Oxf) (2024)
Showing 1-3 of 13628 papers.


Authors: Baeuerle Patrick, et al
Journal: US20200148771A1 2020
Application: ELISA
(2) "Vaccine protection against rectal acquisition of SIVmac239 in rhesus macaques"
Authors: L Gonzalez-Nieto, et al
Journal: PLoS Pathog 2019
Application: ELISA

The following products could also be interesting for you: